Sorafenib in advanced hepatocellular carcinoma: Hypertension as a potential surrogate marker for efficacy

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 36, Issue 4, 2013, Pages 319-324

  Estfan, Bassam ^a   Byrne, Michael ^b   Kim, Richard ^c  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

advanced hepatocellular carcinoma; Child Pugh liver cirrhosis; hypertension; sorafenib; survival

Indexed keywords

ALPHA FETOPROTEIN; SORAFENIB;

ADULT; ADVANCED CANCER; AGED; CANCER SURVIVAL; CHILD PUGH SCORE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DISEASE MARKER; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; FOLLOW UP; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARTIAL HEPATECTOMY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; DATABASES, FACTUAL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPERTENSION; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84881031034     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3182468039     Document Type: Review

References (24)

1. Bosch FX, Ribes J, Cleries R, et al. Epidemiology of hepatocel-lular carcinoma. Clin Liver Dis. 2005;9:191-211, v.
2. Estimated New Cancer Cases and Deaths for 2009. [cited 2011 3/8/2011]; Available from: http://seer.cancer.gov/csr/1975-2006/results-single/sect-01- table.01.pdf.
3. Centers for Disease Control and Prevention (CDC). Hepatocellular carcinoma-United States 2001-2006. Morb Mortal Wkly Rep. 2010;59:517-520.
4. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099-7109.
5. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24:4293-4300.
6. Strumberg D, Voliotis D, Moeller JG, et al. Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors. Int J Clin Pharmacol Ther. 2002;40:580-581.
7. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-390.
8. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-1236.
9. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25-34.
10. Yau T, Chan P, Ng KK, et al. Phase 2 open-label study of singleagent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer. 2009;115:428-436.
11. Richly H, Schultheis B, Adamietz IA, et al. Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial. Eur J Cancer. 2009;45:579-587.
12. Furuse J, Ishii H, Nakachi K, et al. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci. 2008;99:159-165.
13. Shim JH, Park JW, Choi JI, et al. Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area. J Cancer Res Clin Oncol. 2009; 135:617-625.
14. Pinter M, Sieghart W, Graziadei I, et al. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist. 2009;14:70-76.
15. Worns MA, Weinmann A, Pfingst K, et al. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol. 2009;43:489-495.
16. Kim JW, Lee JO, Han SW, et al. Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy. Am J Clin Oncol. 2011;34:125-129.
17. Balsom SM, Li X, Trolli E, et al. A single-institute experience with sorafenib in untreated and previously treated patients with advanced hepatocellular carcinoma. Oncology. 2010;78: 210-212.
18. Lee S, Kang Y, Chang H, et al. Sorafenib in patients with advanced hepatocellular carcinoma: experience in a single institute. ASCO Gastrointestinal Cancers Symposium Abstracts. 2009: abstract 256.
19. Abou-Alfa GK, Amadori D, Santoro A, et al. Is sorafenib (S) safe and effective in patients (pts) with hepatocellular carcinoma (HCC) and Child-Pugh B (CPB) cirrhosis? ASCO Meeting Abstracts. 2008;26 (May 20 Suppl): abstract 4518.
20. Miller AA, Murry DJ, Owzar K, et al. Phase I and pharmacoki-netic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol. 2009;27:1800-1805.
21. Dahlberg SE, Sandler AB, Brahmer JR, et al. Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol. 2010; 28:949-954.
22. Bono P, Elfving H, Utriainen T, et al. Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma. Ann Oncol. 2009;20:393-394.
23. Rini BI, Cohen DP, Lu D, et al. Hypertension (HTN) as a biomarker of efficacy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib. ASCO Genitourinary Cancers Symposium Abstracts. 2010: abstract 312.
24. Rini BI, Schiller JH, Fruhauf JP, et al. Association of diastolic blood pressure (dBP) > 90mm Hg with overall survival (OS) in patients treated with axitinib (AG-013736). ASCO Meeting Abstracts. 2008;26 (May 20 Suppl): abstract 3543.